XVIVO Scientific Animation
  • Services
    • All Services
    • Medical Animation
    • Illustration
    • Interactive
  • About
    • About Us
    • Process
    • Our Team
  • Portfolio
  • Blog
  • Contact

Example Type: Oncology Animation

  • Predator Platform Animation Thumbnail

    Predator Platform Technology Animation

    November 23, 2022

    By Jordan Maire

    XVIVO recently partnered with Werewolf Therapeutics to create an animation about their INDUKINE molecules and how the molecules could transform immunotherapy as it is practiced today.
    Read More
  • Anchored Immunotherapy MOA Animation

    October 17, 2022

    By Jordan Maire

    Ankyra Therapeutics teamed up with XVIVO on a scientific animation touting their anchored immunotherapy approach to cancer treatment, which is designed to promote prolonged immune activation at the tumor site while limiting systemic toxicity that can be associated with other immunotherapy.
    Read More
  • Ociperlimab MOA

    May 4, 2022

    By Jordan Maire

    Designed by BeiGene, Ociperlimab is an investigational monoclonal antibody designed to bind to TIGIT in an effort to combat cancer. Together with BeiGene we created an animation to support their groundbreaking work.
    Read More
  • Sandostatin MOA

    June 9, 2021

    By admin

    Working closely with Maven Communications, we developed a 3D MOA animation for Novartis illustrating the mechanism of action of Sandostatin LAR. Sandostatin LAR is indicated for the treatment of patients with symptoms associated with functional gastroenteropancreatic neuroendocrine tumors.
    Read More
  • SONNET PLATFORM MOA

    April 29, 2021

    By Jordan Maire

    Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.
    Read More
  • A FOCUS ON ALK-POSITIVE NON-SMALL CELL LUNG CANCER

    February 4, 2021

    By admin

    In partnership with Wedgewood Communications, XVIVO developed two videos for Takeda Oncology to discuss lung cancer mechanism of disease and treatments.
    Read More
  • FROM MELANOCYTE TO MELANOMA

    February 4, 2021

    By admin

    Working with MELA Sciences, we designed this medical animation to help doctors and their patients …
    Read More
  • THE ROLE OF SEROTONIN IN CARCINOID SYNDROME

    February 4, 2021

    By admin

    In this video, we will discuss tryptophan metabolism as applied to carcinoid syndrome in patients …
    Read More
  • APOPTOSIS AND BCL-2

    February 4, 2021

    By admin

    ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
    Read More
  • GLEEVEC (IMATINIB) MOA

    February 4, 2021

    By admin

    Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling.
    Read More
  • 1
  • 2
  • Next »

Can't Get Enough of XVIVO?

We’ve got you covered! Check out our latest wallpapers for stunning visuals!

Wallpapers

Contact Us

Have a question, need a quote, or don’t see what you are looking for? Just fill out this brief project inquiry to get in touch with us.

  • This field is for validation purposes and should be left unchanged.
XVIVO Scientific Animation
  • Services
  • Portfolio
  • About
  • Blog
  • Contact
  • Wallpapers
  • 860.721.9848
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
  • Terms & Conditions
Copyright 2023